PureTech Health PLC
LSE:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
LSE:PRTC
Watchlist
Price: 125.6 GBX 1.45% Market Closed
Market Cap: 303.6m GBX

PureTech Health PLC
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

PureTech Health PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
PureTech Health PLC
LSE:PRTC
Revenue
$4.8m
CAGR 3-Years
-35%
CAGR 5-Years
-13%
CAGR 10-Years
8%
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

PureTech Health PLC
Glance View

Market Cap
301.8m GBX
Industry
Biotechnology

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

PRTC Intrinsic Value
HIDDEN
Show

See Also

What is PureTech Health PLC's Revenue?
Revenue
4.8m USD

Based on the financial report for Dec 31, 2024, PureTech Health PLC's Revenue amounts to 4.8m USD.

What is PureTech Health PLC's Revenue growth rate?
Revenue CAGR 10Y
8%

Over the last year, the Revenue growth was 45%. The average annual Revenue growth rates for PureTech Health PLC have been -35% over the past three years , -13% over the past five years , and 8% over the past ten years .

Back to Top